Imiloksan

Imiloksan
IUPAC ime
	(RS)-2-(2,3-dihidro-1,4-benzodioksin-2-ilmetil)-1-etilimidazol
Identifikatori
CAS broj	81167-16-0
ATC kod	none
PubChem	CID 133621
UNII	ZJ56PS1DWK
ChEMBL	CHEMBL578481
Hemijski podaci
Formula	C14H16N2O2
Molarna masa	244,289 g/mol
	SMILES CCN1C=CN=C1CC2COC3=CC=CC=C3O2; ;

Imiloksan je lek koji se koristi u naučnim istraživanjima. On deluje kao selektivni antagonist α_2B adrenergičkog receptora.^[1] On je bio koristan u određivanju dejstva pojedinačnih α₂ adrenergičkih tipova.^[2]^[3]

Hemija[уреди | уреди извор]

Imidazolna porcija imiloksana se priprema reakcijom imidata sa dietil acetalom aminoacetaldehida. N-alkilacija imidazola sa etil jodidom daje imiloksan.^[4]

Reference[уреди | уреди извор]

^ Michel AD, Loury DN, Whiting RL (1990). „Assessment of imiloxan as a selective alpha 2B-adrenoceptor antagonist”. British Journal of Pharmacology. 99 (3): 560—4. PMC 1917331 . PMID 1970500.
^ Cobos-Puc LE, Villalón CM, Sánchez-López A, Lozano-Cuenca J, Pertz HH, Görnemann T, Centurión D (2007). „Pharmacological evidence that alpha2A- and alpha2C-adrenoceptors mediate the inhibition of cardioaccelerator sympathetic outflow in pithed rats”. European Journal of Pharmacology. 554 (2–3): 205—11. PMID 17109851. doi:10.1016/j.ejphar.2006.09.068.
^ Romero TR, de Castro Perez A, de Francischi JN, Gama Duarte ID (2009). „Probable involvement of alpha(2C)-adrenoceptor subtype and endogenous opioid peptides in the peripheral antinociceptive effect induced by xylazine”. European Journal of Pharmacology. 608 (1–3): 23—7. PMID 19236861. doi:10.1016/j.ejphar.2009.02.019.
^ Caroon, Joan M.; Clark, Robin D.; Kluge, Arthur F.; Olah, Ronald; Repke, David B.; Unger, Stefan H.; Michel, Anton D.; Whiting, Roger L. (1982). „Structure-activity relationships for 2-substituted imidazoles as .alpha.2-adrenoceptor antagonists”. Journal of Medicinal Chemistry. 25 (6): 666—70. PMID 6124635. doi:10.1021/jm00348a012.

Spoljašnje veze[уреди | уреди извор]

[pmid1970500-1] Michel AD, Loury DN, Whiting RL (1990). „Assessment of imiloxan as a selective alpha 2B-adrenoceptor antagonist”. British Journal of Pharmacology. 99 (3): 560—4. PMC 1917331 . PMID 1970500.

[pmid17109851-2] Cobos-Puc LE, Villalón CM, Sánchez-López A, Lozano-Cuenca J, Pertz HH, Görnemann T, Centurión D (2007). „Pharmacological evidence that alpha2A- and alpha2C-adrenoceptors mediate the inhibition of cardioaccelerator sympathetic outflow in pithed rats”. European Journal of Pharmacology. 554 (2–3): 205—11. PMID 17109851. doi:10.1016/j.ejphar.2006.09.068.

[pmid19236861-3] Romero TR, de Castro Perez A, de Francischi JN, Gama Duarte ID (2009). „Probable involvement of alpha(2C)-adrenoceptor subtype and endogenous opioid peptides in the peripheral antinociceptive effect induced by xylazine”. European Journal of Pharmacology. 608 (1–3): 23—7. PMID 19236861. doi:10.1016/j.ejphar.2009.02.019.

[4] Caroon, Joan M.; Clark, Robin D.; Kluge, Arthur F.; Olah, Ronald; Repke, David B.; Unger, Stefan H.; Michel, Anton D.; Whiting, Roger L. (1982). „Structure-activity relationships for 2-substituted imidazoles as .alpha.2-adrenoceptor antagonists”. Journal of Medicinal Chemistry. 25 (6): 666—70. PMID 6124635. doi:10.1021/jm00348a012.

[1]

[2]

[3]

[4]